Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

CUT&Tag profiling of H3K18LA modification in rat pancreas with acute pancreatitis

ABSTRACT: This study explores histone modification dynamics in acute pancreatitis. Sprague-Dawley rats were intraperitoneally injected twice with L-arginine (2.5 g/kg, 1-hour interval) to induce acute pancreatitis. Pancreatic tissues were harvested after 48 hours. CUT&Tag was performed using anti-H3K18LA antibody (IP) and corresponding input control to assess promoter-associated chromatin changes in the inflamed pancreas.

ORGANISM(S): Rattus norvegicus

PROVIDER: GSE302970 | GEO | 2025/08/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

CUT&Tag profiling of H3K18LA modification in rat pancreas with acute pancreatitis

Project description:CUT&Tag profiling of H3K18LA modification in rat pancreas with acute pancreatitis

| PRJNA1293177 | ENA

mRNA expression pattern of KrasG12D mice with acute pancreatitis compared with wild-type mice without acute pancreatitis

Project description:Transgenic KrasG12D mice can recapitulate pancreas intra-epithelial neoplasia (PanIN). Caerulein is a cholecystokinin analogue and induces acute pancreatitis when injected intra-abdominally. Caerulein-induced acute pancreatitis will accelerate PanIN progression in KrasG12D mice. We compared mRNA profile changes between KrasG12D mice with acute caerulein-induced pancreatitis and wild-type mice without acute pancreatitis. The experiment had two groups. Experiment group: KrasG12D mice with acute caerulein-induced pancreatitis (N=6). Three mice in experiment group received 1-week caerulein injection, and the other three mice received 2-week caerulein injection. All experiment group mice started to receive caerulein injection at 1-month of age, and were sacrificed at the last day of caerulein injection. Control group: wild-type mice without acute pancreatitis (N=6). The mice were sacrificed at 1.5-month of age. Whole pancreas tissue lysate samples were subjected to mRNA array assay.

2016-05-14 | E-GEOD-77983 | biostudies-arrayexpress

mRNA expression pattern of KrasG12D mice with acute pancreatitis compared with wild-type mice without acute pancreatitis

2016-05-14 | GSE77983 | GEO

Cerulein induced acute pancreatitis in C57Bl/6J

Project description:There still is a lack of specific, early markers for acute pancreatitis. We used the gene expression profiling Affimetrix mouse gene 1.0 ST arrays (Affymetrix , Inc. Santa Clara, CA), to cmpare the gene expression between control mice and mice with induced experimental acute pancreatitis, in order to identify new potential biomarkers of acute pancreatitis.

2018-09-12 | GSE109227 | GEO

H3K18la marks active tissue-specific enhancers [RNA-Seq]

Project description:We profiled the genome-wide distribution of H3K18la in samples originating from 6 different in vitro and in vivo mouse samples, representing 3 tissues: embryonic stem cells, macrophages and skeletal muscle as well as in human skeletal muscle and compared them to the profiles of other well-established histone modifications as well as gene expression patterns. Globally, we found that H3K18la profiles resemble H3K27ac profiles better than any other investigated hPTM, including H3K4me3, but that they do not copy them. For all samples, H3K18la marked active CGI promoters of highly expressed genes which were remarkably shared across the different mouse tissues and which contained many housekeeping genes. Promoter H3K18la levels correlated positively to both H3K27ac and H3K4me3 levels as well as to gene expression levels. In addition, we found that H3K18la is enriched at tissue-type specific, active enhancers, which are particularly tissue-type-specific, especially when compared to the H3K18la-marked promoter regions. Accordingly, enhancer H3K18la levels correlate positively to the expression of their nearest genes. Additionally, genes closest to enhancers with high H3K18la levels predominantly consist of tissue-type specific marker genes. Overall, we showed that H3K18la is not only a marker for active promoters, but that it also marks active enhancers, and this both in embryonic tissues and differentiated tissues, and both in mouse and in human.

2022-09-14 | GSE195859 | GEO

Hepatic transcriptome analysis of control, acute pancreatitis and severe acute pancreatitis mice

Project description:Hepatic transcriptome analysis of control, acute pancreatitis and severe acute pancreatitis mice

| PRJNA637754 | ENA

H3K18la marks active tissue-specific enhancers [Cut & Tag mouse]

2022-09-14 | GSE195856 | GEO

H3K18la marks active tissue-specific enhancers [Cut & Tag human]

2022-09-14 | GSE195854 | GEO

Expression Data from regulatory T-cells in a model of acute pancreatitis

Project description:Foxp3 positive regulatory T-cells were isolated by FACS from spleen of mice with acute pancreatitis induced by partial pancreatic duct ligation, mice without pancreatitis refer as controls we used microarrays to investigate the activation of Tregs during acute pancreatitis

2023-02-01 | GSE196410 | GEO

Effect of kinsenoside on bone marrow-derived macrophages during acute pancreatitis

Project description:Studies have shown that the small molecular compound kinsenoside (KD) can inhibit the M1 polarization of macrophages and inhibit the expression of proinflammatory genes. However, the role of kinsenoside in acute pancreatitis is unclear. Our study showed that intraperitoneal injection of kinsenoside can alleviate acute pancreatitis in mice. In order to find out the main mechanism by which kinsenoside affects the polarization of macrophages in acute pancreatitis, we further performed transcriptomic analysis of bone marrow-derived macrophages (BMDMs) stimulated by injured pancreatic acinar cell conditioned media (PAC-CM) treated with or without kinsenoside. This work provides a potential therapeutic approach for acute pancreatitis.

2025-01-27 | GSE285782 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data